The association of cetuximab with both an EGFR-expressing HNSCC cell and an FcγR-expressing immune cell provides a bridge, inducing antibody-dependent cellular cytotoxicity (ADCC) and subsequent tumor cell elimination [20,21,22,23]. The gene discussed is EGFR; the disease is neoplasm.